Khadija Saeed

May 19, 2026, 3:26 AM EDT. Island Pharmaceuticals Limited (ASX:ILA), a drug repurposing company focusing on antiviral therapeutics in Australia and the U.S., posted a AU$3.9 million loss in the latest financial year and a AU$7.2 million loss over the trailing twelve months. Analysts project the company will break even in 2027 and reach a profit of AU$295 million by 2028. This forecast implies an ambitious average annual growth rate of 140%. Notably, Island Pharmaceuticals operates with no debt, relying solely on shareholder funding, which reduces financial risk typical in cash-burning pharmaceutical firms. Investors anticipate milestone developments but should remain cautious of the high growth assumptions given the volatile nature of pharmaceutical cash flows during drug development phases.